- In September 2025, Lupin's subsidiary formed a partnership with Celnova Pharma to distribute NaMuscla, a medication for non-dystrophic myotonic disorders, in Argentina and Colombia. This collaboration seeks to offer innovative treatment solutions for patients suffering from these rare neuromuscular conditions. The agreement involves the distribution of a drug specifically indicated for treating non-dystrophic myotonic disorders. The pact was established between Lupin Atlantis Holdings SA and Celnova
Frequently Asked Questions
The market is segmented based on Segmentation By Treatment (Anticonvulsant Drugs and Physical Therapy), Route of Administration (Oral, Parenteral, and Others), End-Users (Clinics, Hospitals, Homecare, Therapy Centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Myotonia Treatment Market size was valued at USD 1.23 USD Billion in 2024.
The Global Myotonia Treatment Market is projected to grow at a CAGR of 8.6% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
